SCHEMBL1554909

SCHEMBL1554909

CCn1cc(Br)c(-c2ccc(F)cc2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.44
RAB9A P51151 3/20 0.44
TSHR P16473 2/20 0.41
KMT2A Q03164 3/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
RECQL P46063 1/20 0.39
MEN1 O00255 2/20 0.39
MAPK13 O15264 1/20 0.39
CSNK1D P48730 1/20 0.39
CSNK1E P49674 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
PTGS2 P35354 3/20 0.38
PTGS1 P23219 1/20 0.38
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1555467 0.87 RECQL (0.43) KMT2AALDH1A1RECQLMAPK13CSNK1D
SCHEMBL4305338 0.83 TSHR (0.44) NPC1RAB9ATSHRKMT2AKDM4E
SCHEMBL26111070 0.83 TSHR (0.52) NPC1RAB9ATSHRKMT2AKDM4E
SCHEMBL1554348 0.83 S1PR1 (0.43) TSHRKMT2AKDM4EALDH1A1RECQL
SCHEMBL12684917 0.81 MAPK1 (0.44) NPC1RAB9ATSHRKMT2AKDM4E
SCHEMBL1554008 0.81 MAPK14 (0.43) KMT2AKDM4EALDH1A1RECQLMEN1
SCHEMBL1554556 0.80 CSNK1D (0.44) TSHRKMT2AALDH1A1RECQLMEN1
SCHEMBL1554059 0.80 MAPK14 (0.41) KMT2AKDM4EALDH1A1RECQLMEN1
SCHEMBL25321487 0.78 NPC1 (0.41) NPC1RAB9ATSHRKMT2AKDM4E
SCHEMBL1555212 0.78 MAPK14 (0.44) KMT2AALDH1A1MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236608-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-07-24 US disclosed
EP-4504719-A1 EGFR INHIBITORS Blueprint Medicines Corporation (US) 2025-02-12 EP disclosed
CN-119325471-A EGFR inhibitors 缆图药品公司 2025-01-17 CN disclosed
WO-2023196283-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2023-10-12 WO disclosed
WO-2023196283-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2023-10-12 WO disclosed
EP-2784072-A1 3-PHENYL-4-PYRI(MI)DINYL-1H-PYRAZOLES AND THEIR USE AS FUNGICIDES Bayer CropScience AG (DE) 2014-10-01 EP disclosed
EP-2784073-A1 3-PHENYL-4-PYRI(MI)DINYL-1H-PYRAZOLES AND THEIR USE AS FUNGICIDES Bayer CropScience AG (DE) 2014-10-01 EP disclosed
EP-2784071-A1 3-PHENYL-4-PYRI(MI)DINYL-1H-PYRAZOLES AND THEIR USE AS FUNGICIDES Bayer CropScience AG (DE) 2014-10-01 EP disclosed
EP-2784070-A1 3-PHENYL-4-PYRI(MI)DINYL-1H-PYRAZOLES AND THEIR USE AS FUNGICIDES Bayer CropScience AG (DE) 2014-10-01 EP disclosed
EP-2654750-A1 NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS Pfizer Inc (US) 2013-10-30 EP disclosed
US-20130281455-A1 Phenylpyri(mi)dinylazoles BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-10-24 US disclosed
CN-102834387-A Phenylpyri(mi)dinylpyrazoles and their use as fungicides BAYER CROPSCIENCE AG 2012-12-19 CN disclosed
EP-2486031-A2 Phenylpyri(mi)dinylpyrazoles and their use as fungicides Bayer CropScience AG (DE) 2012-08-15 EP disclosed
WO-2012085721-A1 NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS PFIZER INC. (US) 2012-06-28 WO disclosed
US-20110183978-A1 Phenylpyri(mi)dinylazoles BAYER CROPSCIENCE AG (DE) 2011-07-28 US disclosed
WO-2011042389-A2 PHENYLPYRI(MI)DINYLAZOLES BAYER CROPSCIENCE AG (DE) 2011-04-14 WO disclosed
EP-2308866-A1 Phenylpyri(mi)dinylpyrazoles and their use as fungicides Bayer CropScience AG (DE) 2011-04-13 EP disclosed
EP-2308866-A1 Phenylpyri(mi)dinylpyrazoles and their use as fungicides Bayer CropScience AG (DE) 2011-04-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281455-A1 Phenylpyri(mi)dinylazoles PIR, PIN4, PNN NPC1 3221/4885RAB9A 3531/4885TSHR 3792/4885
US-20110183978-A1 Phenylpyri(mi)dinylazoles PIR, PIN4, PNN NPC1 3221/4885RAB9A 3531/4885TSHR 3792/4885
US-20250236608-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 NPC1 1417/4885RAB9A 446/4885TSHR 976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.